SBT 17th Annual Meeting

Program Schedule

Friday, November 8, 2002
6:00 am-6:00 pm Registration Open
7:00 am-8:00 am Continental Breakfast in the Exhibit Hall
8:00 am-8:15 am President's Welcome and Keynote Address Introduction
Robert O. Dillman, MD
Hoag Cancer Center
8:15 am-9:15 am Keynote Address
The HER2 Alteration in Human Breast Cancer: Therapeutic and Diagnostic Implications
Dennis Slamon, MD, PhD
University of California Los Angeles
9:15 am-9:30 am Refreshment Break
9:30 am-12:15 pm  Joint Session: Antibodies/Immunoconjugates
  Co-Chairs:
Christine A. White, MD
IDEC Pharmaceuticals Corp.

Peter McLaughlin, MD
MD Anderson Cancer Center

9:30 am-9:55 am

Zevalin: The Radiotherapy of Non-Hodgkins Lymphoma
Christine A. White, MD
IDEC Pharmaceuticals Corp.

9:55 am-10:20 am

Rixtuximab, Spectrum of Activity, Mechanisms of Action and Resistance
Peter McLaughlin, MD
MD Anderson Cancer Center

10:20 am-10:45 am

The Role of Alemtuzumab in the Therapy of CLL
Stefan Faderl, MD
MD Anderson Cancer Center

10:45 am-11:10 am

Antibody-Based Treatment of AML
Joseph G. Jurcic, MD
Memorial Sloan-Kettering Cancer Center

11:10 am-11:35 am

Mechanisms of Action of Anti-Tumor Monoclonal Antibodies: Lessons from Apolizumab and Immunostimulatory CpG ODN
George J. Weiner, MD
University of Iowa

11:35 am-11:50 am

Humanized Monoclonal Antibody IGN311 Targeting Lewis Y: Pharmacokinetics and Toxicology in Rhesus Monkeys
Hans Loibner, PhD
Igeneon AG

11:50 am-12:05 pm

Phenotypic Analysis of Peripheral Blood Mononuclear Cells (PBMC) in MDX-010 (Fully Human Anti-CTLA-4 MAb) Treated Cancer Patients
Thomas A. Davis, MD
Medarex, Inc.

12:05 pm-12:20 pm

ABX-EGF, A Fully Human Anti-Epidermal Growth Factor Receptor (EGFr) Monoclonal Antibody (Mab): Results of a Phase 1 Study and a Phase 2 Renal Cell Cancer (RCC) Study
Kenneth A. Foon, MD
Abgenix, Inc.

12:15 pm-2:15 pm Poster Session (authors must be present)
Box lunches will be available in the Scripps Hallway
2:15 pm-5:00 pm Concurrent Sessions 1: Engineered T Cells & IL-2 in Malignancy
  Co-Chairs:
Kim A. Margolin, MD

City of Hope

Michael Jensen, MD
City of Hope/Beckman Research Institute

2:15 pm 2:40 pm The Role of IL-2 in Hematologic Malignancy and Hematopoietic Cell Transplant
Kim A. Margolin, MD
City of Hope
2:40 pm 3:05 pm Adaptive Therapy with Chimeric Immunoreceptor Re-Directed T-Cells
Michael Jensen, MD
City of Hope/Beckman Research Institute
3:05 pm 3:30 pm Mechanisms of Tumor Recognition and Cytolysis by Ex-Vivo Expanded Cells
Michael Verneris
Stanford University
3:30 pm 3:50 pm Refreshment Break
3:50 pm 4:15 pm Recovery of T Cell Populations Post Transplant
Ronald E. Gress, MD
National Cancer Institute, NIH
4:15 pm 4:45 pm Lawrence Cooper, MD, PhD
City of Hope National Medical Center
4:45 pm 5:00 pm Hydrophobically Appended Tumor Antigens Induce High Affinity Cytotoxic T Cells from Ovarian Tumor Associated Lymphocytes
Koichiro Kawano, MD, PhD
MD Anderson Cancer Center
2:15 pm-5:05 pm Concurrent Session 2: Vaccines and Mechanisms of Escape
  Co-Chairs:
Peter Hersey, MD, PhD

Newcastle Mater Hospital

James W. Mier, MD
Beth Israel Deaconess Medical Center

2:15 pm 2:40 pm Resistance Mechanisms in Melanoma Cells to Apoptosis Induced by TRAIL (TNF-related apoptosis inducing ligand)
Peter Hersey, MD, PhD
Newcastle Mater Hospital
2:40 pm 3:05 pm Role of PI-3 Kinase in Regulation of FLIP Expression
James W. Mier, MD
Beth Israel Deaconess Medical Center
3:05 pm 3:30 pm Tumors Alter Sensitivity of T Cells to Apoptosis; Role of Bcl-2 Family Members and Mitochondrial Damage
James H. Finke, PhD
Cleveland Clinic Foundation
3:30 pm 3:50 pm Refreshment Break
3:50 pm 4:05 pm Immunological Analysis of a Phase I/II Study of Vaccination with a MAGE-3 Protein Plus Immunological Adjuvant AS02B in Patients with MAGE-3-Positive Tumors
Maryse Gueguen, PhD
GlaxoSmithKline Biologicals SA
4:05 pm 4:20 pm Immunological and Clinical Responses to a Melanoma Peptide Vaccine Administered in Conjunction with Low-Dose Interleukin-2
Craig Slingluff, MD
University of Virginia
4:20 pm 4:35 pm Chimeric Costimulatory Molecules that Selectively Act Through CD28 or CTLA-4 on T Cells
Margaret Neighbors, PhD
Maxygen
4:35 pm 4:50 pm Analysis of Immune Escape Mechanism of Cancer-Possible Role of Endogenous Polyamine
Toshihiko Torigoe, MD, PhD
Sapporo Medical University
4:50 pm 5:05 pm Transforming Growth Factor-Beta Inhibits the Antigen Presenting Functions and Anti-Tumor Activity of Dendritic Cell Vaccines
James J. Kobie
University of Arizona
5:00 pm -7:00 pm Cocktail Reception in Exhibit Hall
Sponsored by a grant from